Recent Updates
Recently added Catalysts
PRCT Positive Sentiment Score: 75/100

PROCEPT BioRobotics Corp. to Present at the 43rd Annual Cowen Health Care Conference in Boston

Key Takeaway: PROCEPT BioRobotics Corporation will present at the 43rd Annual Cowen Health Care Conference in Boston on March 7. The company focuses on developing advanced surgical robotics solutions in urology, specifically through its AquaBeam Robotic System. The presentation will be live-streamed and available for later viewing. PROCEPT's Aquablation therapy offers effective treatment for men suffering from benign prostatic hyperplasia (BPH), supported by substantial clinical evidence.

Market Sentiment Analysis

POSITIVE FACTORS

  • Company is participating in a prominent healthcare conference, increasing visibility.
  • PROCEPT BioRobotics is focused on transformative solutions in urology.
  • Aquablation therapy has strong clinical evidence supporting its effectiveness.

Full Press Release Details

REDWOOD CITY, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 43rd Annual Cowen Health Care Conference in Boston. Management is scheduled to present on Tuesday, March 7 at 12:50 p.m. Eastern Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
VP, Investor Relations and Business Operations

Frequently Asked Questions

When will PROCEPT BioRobotics present at the Cowen Conference?

PROCEPT BioRobotics will present on March 7 at 12:50 p.m. Eastern Time.

What is the focus of PROCEPT BioRobotics Corporation?

The company focuses on developing innovative solutions in urology through surgical robotics.

What is Aquablation therapy used for?

Aquablation therapy treats lower urinary tract symptoms from benign prostatic hyperplasia.

How many men in the U.S. are affected by BPH?

Approximately 40 million men in the United States are affected by benign prostatic hyperplasia.

Where can I find the webcast recording of the presentation?

The webcast will be available in the 'Investors' section of the company's website.

Last updated: Feb 13, 2023